Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  recurrent breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 204 for your search:
Start Over
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO# 08-1373, NCT00900744
Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-09-14B, NCT00984269
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: A11-3691, NCT01537029
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MM-302-02-02-03, NCT02213744
Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP9881B/3001, NCT00081796
Regional Anesthesia and Breast Cancer Recurrence
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 06-692, NCT00418457
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 114299, NCT01160211
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBKM120F2303, 2012-002571-34, NCT01633060
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PUMA-NER-1301, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG78/BIG 1-13/NSABP-B-54-I, 2013-001040-62, NCT01864746
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PR-30-5010-C, 1307-BCG, BIG5-13, NCT01905592
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011A2301, 2013-003084-61, NCT01958021
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B3271002, REFLECTIONS B327-02, 2013-001352-34, NCT01989676
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7389-A001-303, RU011201I, NCT02037529
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15362, I3Y-MC-JPBL, 2013-004728-13, NCT02107703
Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00746, ECOG-E2112, E2112, U10CA180820, U10CA021115, NCT02115282
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-914, 2014-000345-70, NCT02163694
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15417, I3Y-MC-JPBM, 2014-001502-18, NCT02246621
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLEE011E2301, NCT02278120
SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over, postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO29058, 2014-003185-25, NCT02340221
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0803003591, NCT00719875
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: HCI53993, NCT00748553
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 105-08-201, NCT00826085
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OIC-1UO-C001, NCT01100463
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20080325, SCCC-2008002, NCT01216176
Start Over